WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Exchange
Industry
Zen Score
Market Cap
Price
1d %
EBITDA
P/E
D/E
IMTX
IMMATICS NV
NASDAQ
Biotechnology
$859.28M$10.15-3.65%-$97.57M-7.78x1.27
OCS
OCULIS HOLDING AG
NASDAQ
Biotechnology
$439.06M$11.98-0.25%-$98.97M-3.55x0.22
CRNX
CRINETICS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$3.01B$43.32-2.38%-$212.22M-11.74x0.18
IFRX
INFLARX NV
NASDAQ
Biotechnology
$80.08M$1.362.21%-$45.72M-1.60x0.17
STTK
SHATTUCK LABS INC
NASDAQ
Biotechnology
$470.00M$9.90-1.21%-$82.89M-4.83x0.10
MREO
MEREO BIOPHARMA GROUP PLC
NASDAQ
Biotechnology
$389.92M$2.781.08%-$27.34M-13.90x0.32
PRTC
PURETECH HEALTH PLC
NASDAQ
Biotechnology
$765.50M$27.480.00%-$97.18M-15.27x0.29
APRE
APREA THERAPEUTICS INC
NASDAQ
Biotechnology
$28.07M$5.173.48%-$15.50M-1.31x0.34
QSI
QUANTUM-SI INC
NASDAQ
Biotechnology
$236.76M$1.67-3.59%-$90.40M-2.46x0.10
KRRO
KORRO BIO INC
NASDAQ
Biotechnology
$505.30M$62.99-7.08%-$73.91M-1.19x0.31
VCYT
VERACYTE INC
NASDAQ
Biotechnology
$1.49B$19.90-2.11%-$45.27M-19.51x0.07
CMRX
CHIMERIX INC
NASDAQ
Biotechnology
$80.82M$0.91-1.66%-$82.09M-0.97x0.10
IMCR
IMMUNOCORE HOLDINGS PLC
NASDAQ
Biotechnology
$2.91B$58.47-0.80%-$50.00M-51.74x0.62
VRDN
VIRIDIAN THERAPEUTICS INC
NASDAQ
Biotechnology
$817.86M$13.03-2.53%-$235.32M-2.45x0.11
LQDA
LIQUIDIA CORP
NASDAQ
Biotechnology
$954.15M$12.55-1.43%-$69.65M-10.37x1.50
BLUE
BLUEBIRD BIO INC
NASDAQ
Biotechnology
$100.92M$0.92-1.19%-$95.08M-1.54x1.76
ATAI
ATAI LIFE SCIENCES NV
NASDAQ
Biotechnology
$310.47M$1.87-1.60%-$35.85M-7.48x0.20
YMAB
Y-MABS THERAPEUTICS INC
NASDAQ
Biotechnology
$669.35M$15.29-2.94%-$24.94M-31.20x0.27
GLMD
GALMED PHARMACEUTICALS LTD
NASDAQ
Biotechnology
$2.02M$0.40-1.75%-$7.46M-0.16x0.20
DNTH
DIANTHUS THERAPEUTICS INC
NASDAQ
Biotechnology
$625.67M$21.32-1.55%-$43.20M-2.52x0.06
AUPH
AURINIA PHARMACEUTICALS INC
NASDAQ
Biotechnology
$727.43M$5.03-3.18%-$63.05M-9.31x0.45
QNCX
QUINCE THERAPEUTICS INC
NASDAQ
Biotechnology
$45.81M$1.06-2.83%-$31.26M-1.26x0.97
ARVN
ARVINAS INC
NASDAQ
Biotechnology
$2.22B$32.54-2.89%-$359.70M-4.92x0.98
MESO
MESOBLAST LTD
NASDAQ
Biotechnology
$631.21M$6.22-1.13%N/A-6.82x0.32
HOTH
HOTH THERAPEUTICS INC
NASDAQ
Biotechnology
$5.15M$1.170.00%-$7.85M-0.51x0.08
MOLN
MOLECULAR PARTNERS AG
NASDAQ
Biotechnology
$127.47M$3.880.00%-$61.83M-1.81x0.12
CYCN
CYCLERION THERAPEUTICS INC
NASDAQ
Biotechnology
$7.51M$2.779.75%-$5.62M-1.23x0.19
BEAM
BEAM THERAPEUTICS INC
NASDAQ
Biotechnology
$1.86B$22.74-5.01%-$111.15M-13.22x0.49
MTEM
MOLECULAR TEMPLATES INC
NASDAQ
Biotechnology
$8.81M$1.64-2.44%$1.16M0.91x7.40
CASI
CASI PHARMACEUTICALS INC
NASDAQ
Biotechnology
$32.64M$2.44-5.74%-$22.29M-1.21x2.12
CRBU
CARIBOU BIOSCIENCES INC
NASDAQ
Biotechnology
$347.71M$3.85-2.34%-$96.30M-2.79x0.17
ABSI
ABSCI CORP
NASDAQ
Biotechnology
$510.91M$4.53-1.66%-$95.46M-3.78x0.23
CCCC
C4 THERAPEUTICS INC
NASDAQ
Biotechnology
$443.85M$6.47-3.55%-$121.80M-2.42x0.53
NTLA
INTELLIA THERAPEUTICS INC
NASDAQ
Biotechnology
$2.03B$21.17-5.43%-$472.22M-3.91x0.24
XOMA
XOMA CORP
NASDAQ
Biotechnology
$298.09M$25.64-1.09%-$39.24M-6.35x1.64
CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC
NASDAQ
Biotechnology
$6.53M$4.81-8.52%-$5.19M-1.28x0.04
ARQT
ARCUTIS BIOTHERAPEUTICS INC
NASDAQ
Biotechnology
$847.12M$8.75-1.83%-$227.43M-2.31x2.85
SPRC
SCISPARC LTD
NASDAQ
Biotechnology
$1.33M$1.214.13%$1.87M-0.30x0.21
KROS
KEROS THERAPEUTICS INC
NASDAQ
Biotechnology
$2.02B$56.24-3.65%-$150.63M-10.82x0.11
SRPT
SAREPTA THERAPEUTICS INC
NASDAQ
Biotechnology
$11.66B$124.252.53%-$461.21M-21.42x2.80
GTHX
G1 THERAPEUTICS INC
NASDAQ
Biotechnology
$208.28M$3.99-3.26%-$34.30M-4.29x2.44
GLYC
GLYCOMIMETICS INC
NASDAQ
Biotechnology
$119.56M$1.86-7.82%-$35.89M-3.20x0.18
QTTB
Q32 BIO INC
NASDAQ
Biotechnology
$85.88M$26.596.21%-$110.32M-0.76x0.16
IKNA
IKENA ONCOLOGY INC
NASDAQ
Biotechnology
$62.25M$1.291.55%-$65.59M-0.79x0.13
SWTX
SPRINGWORKS THERAPEUTICS INC
NASDAQ
Biotechnology
$3.20B$43.381.89%-$321.78M-8.42x0.16
INO
INOVIO PHARMACEUTICALS INC
NASDAQ
Biotechnology
$237.44M$10.16-0.34%-$130.39M-1.67x0.46
IMNM
IMMUNOME INC
NASDAQ
Biotechnology
$851.84M$14.27-0.07%-$106.08M-2.65x0.24
ALLO
ALLOGENE THERAPEUTICS INC
NASDAQ
Biotechnology
$514.04M$3.04-6.09%-$313.07M-1.45x0.26
PLUR
PLURI INC
NASDAQ
Biotechnology
$26.39M$5.09-3.73%-$21.99M-1.10x7.94
CUE
CUE BIOPHARMA INC
NASDAQ
Biotechnology
$69.07M$1.42-0.70%-$46.05M-1.28x0.66
MIST
MILESTONE PHARMACEUTICALS INC
NASDAQ
Biotechnology
$88.23M$1.66-4.82%-$57.04M-1.19x3.49
MRNA
MODERNA INC
NASDAQ
Biotechnology
$41.59B$108.85-2.45%-$3.32B-8.83x0.33
MRNS
MARINUS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$78.69M$1.44-1.39%-$125.31M-0.55x9.19
ABCL
ABCELLERA BIOLOGICS INC
NASDAQ
Biotechnology
$1.14B$3.90-6.92%-$143.14M-7.65x0.29
LYEL
LYELL IMMUNOPHARMA INC
NASDAQ
Biotechnology
$584.42M$2.30-4.35%-$214.38M-2.47x0.15
DNLI
DENALI THERAPEUTICS INC
NASDAQ
Biotechnology
$2.17B$15.56-3.86%-$128.47M-14.68x0.12
TARS
TARSUS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$1.12B$32.76-1.68%-$131.13M-7.09x0.35
PGEN
PRECIGEN INC
NASDAQ
Biotechnology
$353.47M$1.42-1.41%-$89.23M-3.64x0.28
SXTP
60 DEGREES PHARMACEUTICALS INC
NASDAQ
Biotechnology
$2.80M$0.24-3.31%-$1.38M-0.24x0.61
COCP
COCRYSTAL PHARMA INC
NASDAQ
Biotechnology
$15.83M$1.56-2.96%-$17.16M-0.83x0.19
CVKD
CADRENAL THERAPEUTICS INC
NASDAQ
Biotechnology
$6.85M$0.43-0.93%-$8.34M-0.69x0.11
PALI
PALISADE BIO INC
NASDAQ
Biotechnology
$5.41M$6.35-1.89%-$12.20M-0.24x0.24
MGNX
MACROGENICS INC
NASDAQ
Biotechnology
$980.18M$15.70-8.47%$5.51M-104.67x0.96
NGNE
NEUROGENE INC
NASDAQ
Biotechnology
$388.55M$30.23-1.19%-$32.35M1.09x0.20
SLRN
ACELYRIN INC
NASDAQ
Biotechnology
$449.53M$4.57-7.22%-$381.37M-0.84x0.13
LXRX
LEXICON PHARMACEUTICALS INC
NASDAQ
Biotechnology
$393.98M$1.60-3.75%-$163.46M-2.00x1.46
ALPN
ALPINE IMMUNE SCIENCES INC
NASDAQ
Biotechnology
$4.23B$64.570.08%-$31.41M-100.89x0.16
OVID
OVID THERAPEUTICS INC
NASDAQ
Biotechnology
$222.74M$3.15-5.08%-$50.74M-4.26x0.64
LUMO
LUMOS PHARMA INC
NASDAQ
Biotechnology
$22.66M$2.80-1.25%-$34.02M-0.67x0.49
NAUT
NAUTILUS BIOTECHNOLOGY INC
NASDAQ
Biotechnology
$300.24M$2.40-1.67%-$57.97M-4.71x0.15
ABEO
ABEONA THERAPEUTICS INC
NASDAQ
Biotechnology
$86.72M$3.170.63%-$50.57M-1.25x3.32
PPBT
PURPLE BIOTECH LTD
NASDAQ
Biotechnology
$10.18M$0.510.58%$22.27MN/A0.29
ALEC
ALECTOR INC
NASDAQ
Biotechnology
$502.68M$5.25-8.38%-$116.33M-3.37x3.64
KRON
KRONOS BIO INC
NASDAQ
Biotechnology
$57.69M$0.962.08%-$107.76M-0.49x0.34
INVA
INNOVIVA INC
NASDAQ
Biotechnology
$958.53M$15.16-1.12%$248.96M5.51x0.84
VIR
VIR BIOTECHNOLOGY INC
NASDAQ
Biotechnology
$1.09B$8.04-5.10%-$601.03M-1.75x0.21
KYMR
KYMERA THERAPEUTICS INC
NASDAQ
Biotechnology
$2.15B$35.21-5.28%-$143.20M-13.97x0.46
LYRA
LYRA THERAPEUTICS INC
NASDAQ
Biotechnology
$312.46M$5.23-1.15%-$62.34M-4.15x0.60
ANAB
ANAPTYSBIO INC
NASDAQ
Biotechnology
$515.72M$19.27-2.08%-$161.25M-3.17x4.14
ATXS
ASTRIA THERAPEUTICS INC
NASDAQ
Biotechnology
$494.13M$9.001.89%-$72.89M-3.72x0.05
CRDF
CARDIFF ONCOLOGY INC
NASDAQ
Biotechnology
$186.75M$4.18-4.55%-$41.04M-4.49x0.17
HOWL
WEREWOLF THERAPEUTICS INC
NASDAQ
Biotechnology
$273.09M$6.39-2.82%-$30.89M-6.09x0.57
ELVN
ENLIVEN THERAPEUTICS INC
NASDAQ
Biotechnology
$723.17M$17.49-4.06%-$70.98M-8.70x0.11
TTNP
TITAN PHARMACEUTICALS INC
NASDAQ
Biotechnology
$6.37M$6.970.00%-$5.46M-0.94x0.22
TRVI
TREVI THERAPEUTICS INC
NASDAQ
Biotechnology
$182.74M$2.65-4.15%-$28.58M-9.14x0.08
AVXL
ANAVEX LIFE SCIENCES CORP
NASDAQ
Biotechnology
$280.00M$3.41-0.59%-$43.04M-6.20x0.09
TVTX
TRAVERE THERAPEUTICS INC
NASDAQ
Biotechnology
$414.74M$5.45-1.10%-$61.31M-3.63x2.93
CLDX
CELLDEX THERAPEUTICS INC
NASDAQ
Biotechnology
$2.07B$37.02-2.05%-$138.42M-12.68x0.09
VCEL
VERICEL CORP
NASDAQ
Biotechnology
$2.23B$46.11-1.43%$8.93M-658.71x0.57
RLAY
RELAY THERAPEUTICS INC
NASDAQ
Biotechnology
$832.99M$6.35-3.07%-$336.70M-2.28x0.12
ATOS
ATOSSA THERAPEUTICS INC
NASDAQ
Biotechnology
$187.96M$1.501.33%-$30.07M-6.25x0.06
DTIL
PRECISION BIOSCIENCES INC
NASDAQ
Biotechnology
$67.92M$9.82-1.02%-$50.83M-0.62x7.47
LABP
LANDOS BIOPHARMA INC
NASDAQ
Biotechnology
$69.13M$22.181.40%-$21.94M-6.34x0.20
IOBT
IO BIOTECH INC
NASDAQ
Biotechnology
$96.19M$1.46-0.68%-$84.48M-0.74x0.13
RIGL
RIGEL PHARMACEUTICALS INC
NASDAQ
Biotechnology
$197.30M$1.13-2.22%-$16.98M-8.04x-5.09
TERN
TERNS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$307.10M$4.75-2.32%-$89.09M-3.74x0.05
ETNB
89BIO INC
NASDAQ
Biotechnology
$802.24M$8.58-3.85%-$133.26M-4.29x0.11
EVGN
EVOGENE LTD
NASDAQ
Biotechnology
$33.84M$0.67-1.49%-$20.34M-1.29x1.86
LRMR
LARIMAR THERAPEUTICS INC
NASDAQ
Biotechnology
$412.15M$6.46-2.01%-$36.64M-7.69x0.17
PMCB
PHARMACYTE BIOTECH INC
NASDAQ
Biotechnology
$18.62M$2.20-3.64%-$1.14M-1.83x0.72

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -30.41% over the past year, underperforming other biotech stocks by -7 percentage points.

Incyte has an average 1 year price target of $74.69, an upside of 44.36% from Incyte's current stock price of $51.74.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 23.08% have issued a Strong Buy rating, 23.08% have issued a Buy, 53.85% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 47 points higher than the biotech industry average of 23. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -8.91% over the past year, overperforming other biotech stocks by 15 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $37.33, an upside of 27.72% from Harmony Biosciences Holdings's current stock price of $29.23.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 16.67% have issued a Sell rating, and 16.67% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock lose -1.33% over the past year, overperforming other biotech stocks by 22 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 170.81% from Voyager Therapeutics's current stock price of $7.57.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 14.18%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 53.68%, which is 40 percentage points higher than the biotech industry average of 14.18%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)


Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.09%, which is -13 percentage points lower than the biotech industry average of 14.18%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -0.75% in the last day, and down -1% over the last week. Acrivon Therapeutics was the among the top losers in the biotechnology industry, dropping -10.84% yesterday.

Acrivon Therapeutics shares are trading higher after the company reported initial clinical data for ACR-368 and pipeline program progress today at a corporate R&D event.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -21.04% in the past year. It has overperformed other stocks in the biotech industry by 3 percentage points.

2. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has dropped -1.33% in the past year. It has overperformed other stocks in the biotech industry by 22 percentage points.

3. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 71 points higher than the biotech industry average of 15. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -30.41% in the past year. It has underperformed other stocks in the biotech industry by -7 percentage points.

Are biotech stocks a good buy now?

49.32% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 88.37% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 15.69x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.